Protocol Ledger

NCT06782373 · Phase II · RECRUITING

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Interventional Phase II clinical trial protocol NCT06782373 sponsored by Swedish Orphan Biovitrum in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-28 Enrollment: 156 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06782373
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)156 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06782373
Protocol FieldVerified Registry Value
NCT IdentifierNCT06782373
Consolidated Lead SponsorSwedish Orphan Biovitrum
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment156 participants (ESTIMATED)
Registered Start Date2025-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06782373
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Dana-Farber Cancer InstituteBoston, MAOpen Hospital Dossier ->
Mayo Clinic RochesterRochester, MNOpen Hospital Dossier ->
NYU Langone Health and Perlmutter Cancer CenterNew York, NYOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI